Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Effects of cyp2d6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Affiliation:
      1Moscow Research and Practical Centre on Addictions of the Moscow, Department of Healthcare
      2Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation
      3NRC Institute of Immunology FMBA of Russia
      4I.M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation (Sechenov University)
      5Russian Medical Academy of Continuous Professional Education, Ministry of Health of the Russian Federation
      6Department of Psychiatry and Addictions, Saint-Petersburg State University
      7Day In-patient Department, Saint-Petersburg Psychiatric Hospital No. 1 named after P.P. Kashchenko
    • Publication Date:
      2019
    • Author Keywords:
      CYP2D6
      Mirtazapine
      Personalized medicine
      Pharmacogenomics
      Pinoline
    • ISSN:
      12057541
      00084212
    • Accession Number:
      10.1139/cjpp-2019-0177
    • Rights:
      Copyright 2019 Elsevier B.V., All rights reserved.
    • Accession Number:
      edselc.2-52.0-85069873221
  • Citations
    • ABNT:
      ZASTROZHIN, M. S. ( 1,2 ) et al. Effects of cyp2d6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder. Canadian Journal of Physiology and Pharmacology, [s. l.], v. 97, n. 8, p. 781–785, [s. d.]. DOI 10.1139/cjpp-2019-0177. Disponível em: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edselc&AN=edselc.2-52.0-85069873221. Acesso em: 29 nov. 2020.
    • AMA:
      Zastrozhin MS( 1,2 ), Skryabin VY( 1 ), Bryun EA( 1,2 ), et al. Effects of cyp2d6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder. Canadian Journal of Physiology and Pharmacology. 97(8):781-785. doi:10.1139/cjpp-2019-0177
    • APA:
      Zastrozhin, M. S. ( 1,2 ), Skryabin, V. Y. ( 1 ), Bryun, E. A. ( 1,2 ), Smirnov, V. V. ( 3,4 ), Grishina, E. A. ( 5 ), Ryzhikova, K. A. ( 5 ), Sychev, D. A. ( 5 ), & Chumakov, E. M. ( 6,7 ). (n.d.). Effects of cyp2d6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder. Canadian Journal of Physiology and Pharmacology, 97(8), 781–785. https://doi.org/10.1139/cjpp-2019-0177
    • Chicago/Turabian: Author-Date:
      Zastrozhin, M.S. ( 1,2 ), V.Y. ( 1 ) Skryabin, E.A. ( 1,2 ) Bryun, V.V. ( 3,4 ) Smirnov, E.A. ( 5 ) Grishina, K.A. ( 5 ) Ryzhikova, D.A. ( 5 ) Sychev, and E.M. ( 6,7 ) Chumakov. 2020. “Effects of Cyp2d6 Activity on the Efficacy and Safety of Mirtazapine in Patients with Depressive Disorders and Comorbid Alcohol Use Disorder.” Canadian Journal of Physiology and Pharmacology 97 (8): 781–85. Accessed November 29. doi:10.1139/cjpp-2019-0177.
    • Harvard:
      Zastrozhin, M. S. ( 1,2 ) et al. (no date) ‘Effects of cyp2d6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder’, Canadian Journal of Physiology and Pharmacology, 97(8), pp. 781–785. doi: 10.1139/cjpp-2019-0177.
    • Harvard: Australian:
      Zastrozhin, MS( 1,2 ), Skryabin, VY( 1 ), Bryun, EA( 1,2 ), Smirnov, VV( 3,4 ), Grishina, EA( 5 ), Ryzhikova, KA( 5 ), Sychev, DA( 5 ) & Chumakov, EM( 6,7 ) n.d., ‘Effects of cyp2d6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder’, Canadian Journal of Physiology and Pharmacology, vol. 97, no. 8, pp. 781–785, viewed 29 November 2020, .
    • MLA:
      Zastrozhin, M. S. (.1,2 )., et al. “Effects of Cyp2d6 Activity on the Efficacy and Safety of Mirtazapine in Patients with Depressive Disorders and Comorbid Alcohol Use Disorder.” Canadian Journal of Physiology and Pharmacology, vol. 97, no. 8, pp. 781–785. EBSCOhost, doi:10.1139/cjpp-2019-0177. Accessed 29 Nov. 2020.
    • Chicago/Turabian: Humanities:
      Zastrozhin, M.S. ( 1,2 ), V.Y. ( 1 ) Skryabin, E.A. ( 1,2 ) Bryun, V.V. ( 3,4 ) Smirnov, E.A. ( 5 ) Grishina, K.A. ( 5 ) Ryzhikova, D.A. ( 5 ) Sychev, and E.M. ( 6,7 ) Chumakov. “Effects of Cyp2d6 Activity on the Efficacy and Safety of Mirtazapine in Patients with Depressive Disorders and Comorbid Alcohol Use Disorder.” Canadian Journal of Physiology and Pharmacology 97, no. 8: 781–85. Accessed November 29, 2020. doi:10.1139/cjpp-2019-0177.
    • Vancouver/ICMJE:
      Zastrozhin MS( 1,2 ), Skryabin VY( 1 ), Bryun EA( 1,2 ), Smirnov VV( 3,4 ), Grishina EA( 5 ), Ryzhikova KA( 5 ), et al. Effects of cyp2d6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder. Canadian Journal of Physiology and Pharmacology [Internet]. [cited 2020 Nov 29];97(8):781–5. Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edselc&AN=edselc.2-52.0-85069873221